Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 3/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.61 |
| ▸ | RAB9A | P51151 | 3/20 | 0.61 |
| ▸ | JAK3 | P52333 | 2/20 | 0.49 |
| ▸ | JAK1 | P23458 | 1/20 | 0.49 |
| ▸ | TYK2 | P29597 | 1/20 | 0.49 |
| ▸ | TYRO3 | Q06418 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | THRB | P10828 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ATR | Q13535 | 2/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.43 |
| ▸ | FYN | P06241 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | STAT1 | P42224 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2797600 | 0.79 | JAK2 (0.51) | JAK2NPC1RAB9AJAK3JAK1 | |
| SCHEMBL2800273 | 0.79 | JAK2 (0.72) | JAK2NPC1RAB9AJAK3TYRO3 | |
| SCHEMBL2799496 | 0.77 | JAK2 (0.60) | JAK2NPC1RAB9AJAK3JAK1 | |
| SCHEMBL2798916 | 0.77 | JAK2 (0.77) | JAK2JAK3JAK1TYK2FYN | |
| SCHEMBL1463425 | 0.77 | RAB9A (1.00) | JAK2NPC1RAB9AJAK3TYRO3 | |
| SCHEMBL2800365 | 0.77 | JAK2 (0.66) | JAK2NPC1RAB9AJAK3JAK1 | |
| SCHEMBL11889767 | 0.77 | JAK2 (0.55) | JAK2JAK3JAK1TYK2ATR | |
| SCHEMBL2797602 | 0.75 | JAK2 (0.58) | JAK2JAK3JAK1TYK2ALDH1A1 | |
| SCHEMBL2798952 | 0.74 | JAK2 (0.72) | JAK2NPC1RAB9AJAK3JAK1 | |
| SCHEMBL27797907 | 0.74 | JAK2 (0.43) | JAK2JAK3JAK1TYK2ATR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2155201-B1 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2012-08-01 | — | — | EP | claimed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | claimed |
| EP-2155201-B1 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2012-08-01 | — | — | EP | disclosed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-8193189-B2 | Quinoxaline derivatives as tyrosine kinase activity inhibitors | NOVARTIS AG (CH) | 2012-06-05 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | NOVARTIS AG | 2010-07-01 | — | — | US | disclosed |
| WO-2008148867-A2 | QUINOXALINE DERIVATIVES AS INHIBITORS OF THE TYROSINE KINASE ACTIVITY OF JANUS KINASES | NOVARTIS AG (CH) | 2008-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168062-A1 | Quinoxaline Derivatives as Tyrosine Kinase Activity Inhibitors | JAK2, JAK1, JAK3 | JAK2 1/4885NPC1 4739/4885RAB9A 434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.